IRISanRaf

PICCONI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.947
AS - Asia 2.007
EU - Europa 483
Continente sconosciuto - Info sul continente non disponibili 67
SA - Sud America 60
AF - Africa 17
OC - Oceania 14
Totale 5.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.562
TR - Turchia 939
CN - Cina 528
SG - Singapore 467
CA - Canada 385
IT - Italia 140
CZ - Repubblica Ceca 119
EU - Europa 67
BR - Brasile 55
DE - Germania 52
IE - Irlanda 44
GB - Regno Unito 41
IN - India 19
FI - Finlandia 17
HK - Hong Kong 13
FR - Francia 11
RU - Federazione Russa 11
RO - Romania 10
AU - Australia 8
NL - Olanda 7
UA - Ucraina 7
DK - Danimarca 6
JP - Giappone 6
NZ - Nuova Zelanda 6
SC - Seychelles 6
TW - Taiwan 6
ES - Italia 5
BD - Bangladesh 4
BE - Belgio 3
EG - Egitto 3
IL - Israele 3
ZA - Sudafrica 3
CL - Cile 2
CO - Colombia 2
ID - Indonesia 2
IR - Iran 2
LK - Sri Lanka 2
MA - Marocco 2
NG - Nigeria 2
PH - Filippine 2
PK - Pakistan 2
PS - Palestinian Territory 2
SE - Svezia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
GR - Grecia 1
IQ - Iraq 1
JO - Giordania 1
KE - Kenya 1
KR - Corea 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PL - Polonia 1
PT - Portogallo 1
SA - Arabia Saudita 1
UY - Uruguay 1
VN - Vietnam 1
Totale 5.595
Salva come PNG Salva come JPEG
Città #
Kocaeli 807
San Mateo 688
Toronto 373
Wilmington 202
Houston 181
Chandler 159
Santa Clara 153
Lawrence 139
Princeton 139
Singapore 134
Olomouc 119
Beijing 109
Fairfield 84
Ashburn 83
Shanghai 59
Woodbridge 48
Seattle 46
Guangzhou 37
Redwood City 34
The Dalles 25
Shenzhen 23
Cambridge 22
Dublin 22
Los Angeles 20
Rome 20
Falls Church 19
Jiaxing 15
Helsinki 13
Hong Kong 13
Munich 11
Wuhan 11
Brooklyn 10
Constanta 10
Pune 9
Council Bluffs 7
Rui'an 7
Chicago 6
Dongyang 6
São Paulo 6
Wuxi 6
Belo Horizonte 5
Bristol 5
Haining 5
Padova 5
Saint Louis 5
Dallas 4
Espoo 4
Genoa 4
Nanjing 4
Quanzhou 4
Redmond 4
Shaoxing 4
Taipei 4
Tokyo 4
Trento 4
Washington 4
Xi'an 4
Buffalo 3
Florence 3
Franz Josef 3
Hangzhou 3
Kunming 3
Kyiv 3
London 3
Madrid 3
Nantong 3
Opelousas 3
Taizhou 3
Zhengzhou 3
Abuja 2
Assago 2
Boardman 2
Bogotá 2
Bolzano 2
Carasco 2
Dalian 2
Edmonton 2
Filago 2
Fuzhou 2
Guarulhos 2
Handan 2
Hefei 2
Huzhou 2
Imola 2
Istanbul 2
Jakarta 2
Jinan 2
Jinhua 2
Johnstown 2
Kemerovo 2
Kumar 2
Leicester 2
Madison 2
Manassas 2
Manaus 2
Nanning 2
New Delhi 2
Norwalk 2
Novokuznetsk 2
Ottawa 2
Totale 4.046
Salva come PNG Salva come JPEG
Nome #
Direct and indirect pathways of basal ganglia: a critical reappraisal 165
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 136
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease 84
A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation 82
Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 76
Corrigendum: Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 73
Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. 65
Quantal release of dopamine and action potential firing detected in midbrain neurons by multifunctional diamond-based microarrays 65
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease 61
Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. 57
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. 56
Synaptic dysfunction in Parkinson's disease 52
Dopaminergic control of synaptic plasticity in the dorsal striatum 51
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias 50
Theta-burst stimulation and striatal plasticity in experimental parkinsonism 49
Dopamine drives binge-like consumption of a palatable food in experimental parkinsonism. 49
BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior 49
Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum 49
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 49
NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. 48
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. 48
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors 48
NMDA receptor G1uN2D subunit participates to levodopa-induced dyskinesia pathophysiology 48
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts 47
A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication 47
Interaction between basal ganglia and limbic circuits in learning and memory processes 47
Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates 47
A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity 47
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. 46
Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine 46
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities 46
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 46
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models 46
Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission 46
A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. 46
Tissue plasminogen activator is required for corticostriatal long-term potentiation 45
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 45
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. 45
Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease 45
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. 44
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuo-spatial memory alteration. 44
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap 44
Neural networks and synaptic plasticity in Parkinson's disease: beyond motor deficits 44
N-Methyl-D-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons 44
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors 44
Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons 44
Mechanisms underlying dopaminergic control of cortico-striatal synaptic transmission 43
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. 43
Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression 43
Striatum-hippocampus balance: From physiological behavior to interneuronal pathology 43
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism 43
New Synaptic and Molecular Targets for Neuroprotection in Parkinson's Disease 43
An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease 43
Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons 43
Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum 43
Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? 42
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias 42
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias 42
Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. 42
Prenatal stress and hippocampal BDNF expression: a fading imperative 42
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? 41
Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment 41
Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice 41
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D-2/A(2A) Receptor Interaction in the Striatum: Implications for Parkinson's Disease 41
Stimulation of D1/PKA/DARPP-32/PP-1 pathway is required for corticostriatal LTD and LTP 41
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit 41
Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice 40
NR2B subunit exerts a critical role in postischemic synaptic plasticity. 40
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia 40
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia 40
Unilateral dopamine denervation blocks corticostriatal LTP 39
Striatal spreading depolarization: possible implication in L-DOPA-induced dyskinetic like-behavior. 39
Molecular mechanisms underlying levodopa-induced dyskinesia. 39
Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease 39
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission 39
Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. 38
NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients 38
mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP 38
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment 38
Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid 38
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine 38
Intermittent Theta-burst Stimulation Rescues Dopamine-Dependent Corticostriatal Synaptic Plasticity and Motor Behavior in Experimental Parkinsonism: Possible Role of Glial Activity 38
Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. 37
FUNCTIONAL INTERACTIONS WITHIN STRIATAL MICROCIRCUIT IN ANIMAL MODELS OF HUNTINGTON'S DISEASE 37
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission 37
Dopamine-mediated regulation of corticostriatal synaptic plasticity. 37
Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study 37
The endocannabinoid system in Parkinson's disease. 37
Targeting Metabotropic Glutamate Receptors as a New Strategy Against Levodopa-Induced Dyskinesia in Parkinson's Disease? 37
Hyperkinetic disorders and loss of synaptic downscaling 37
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. 37
Deficits of glutamate transmission in the striatum of experimental hemiballism. 37
Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. 36
Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons 36
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia 36
Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease 36
Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. 36
Plastic abnormalities in experimental Huntington's disease 36
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. 36
Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. 35
Totale 4.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.690
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202089 0 0 0 0 0 0 0 0 0 0 0 89
2020/20211.362 89 58 33 11 44 92 70 22 35 48 807 53
2021/20221.349 11 369 372 1 9 12 89 139 36 279 11 21
2022/2023647 308 15 13 54 33 16 5 21 29 63 82 8
2023/2024571 0 2 17 127 26 17 15 37 3 21 70 236
2024/20251.292 54 338 98 68 92 234 41 98 191 20 58 0
Totale 5.845